{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:06:46Z","timestamp":1784642806029,"version":"3.55.0"},"reference-count":31,"publisher":"BMJ","issue":"12","funder":[{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"crossref","award":["BRC184\/III\/ME"],"award-info":[{"award-number":["BRC184\/III\/ME"]}],"id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"VersusArthritis","award":["20873"],"award-info":[{"award-number":["20873"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,11,22]]},"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Few treatment options exist for patients with systemic lupus erythematosus (SLE) who fail conventional therapy. Although widely used to treat lupus, the efficacy of B cell depletion therapy using rituximab has not been demonstrated in randomised clinical trials. Following rituximab, elevated levels of serum B cell activating factor (BAFF) have been associated with failure to remit or subsequent lupus relapse. The administration of belimumab, a monoclonal antibody specific for BAFF and approved for lupus therapy, could potentiate the efficacy of rituximab and enable longer periods of disease remission. The aim of this trial is to assess the safety and efficacy of belimumab following rituximab in patients with SLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>BEAT Lupus is a double-blind, randomised, placebo controlled, phase II clinical trial. Patients with SLE commencing a treatment cycle of rituximab (two 1g infusions, 2\u2009weeks apart) as standard of care will be randomised to receive belimumab or placebo, 4 to 8 weeks following the first rituximab infusion. Belimumab or placebo infusions are administered for 52 weeks. The primary outcome measure is anti-double stranded DNA (anti-dsDNA) antibody levels at 52 weeks. Secondary outcomes include measures of adverse events, lupus disease activity and cumulative steroid dose. The kinetics of B cell repopulation will be assessed in a subgroup of participants. Belimumab administration after rituximab may provide a novel therapeutic pathway for patients with active lupus if safety is demonstrated in this proof of concept study, and lower anti-dsDNA antibodies levels are achieved in those patients treated with belimumab compared with placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>\n                      The protocol has been reviewed and approved by the Hampstead Research Ethics Committee - London (reference 16\/LO\/1024). Trial information is available at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN47873003\">https:\/\/www.isrctn.com\/ISRCTN47873003<\/jats:ext-link>\n                      , and the results of this trial will be submitted for publication in relevant peer-reviewed journals. Key findings will also be presented at national and international conferences.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"ISRCTN47873\">ISRCTN47873<\/jats:ext-link>\n                      ; date assigned to the registry: 28 November 2016. The stage is pre-results.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-032569","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T04:05:23Z","timestamp":1576555523000},"page":"e032569","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":44,"title":["Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct03312907","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02260934","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alexis","family":"Jones","sequence":"first","affiliation":[{"name":"Centre for Rheumatology, Division of Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6824-578X","authenticated-orcid":false,"given":"Patrick","family":"Muller","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline J","family":"Dore","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Ikeji","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Caverly","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashfia","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9514-2455","authenticated-orcid":false,"given":"David A","family":"Isenberg","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology, Division of Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gordon","sequence":"additional","affiliation":[{"name":"Rheumatology Research Team - Inflammation and Ageing (IIA), University of Birmingham Research Laboratories, New Queen Elizabeth Hospital, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-743X","authenticated-orcid":false,"given":"Michael R","family":"Ehrenstein","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology, Division of Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"key":"2025121400422537000_9.12.e032569.1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1586\/1744666X.2016.1112270","article-title":"Why, why, why de-lupus (does so badly in clinical trials)","volume":"12","author":"Isenberg","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"2025121400422537000_9.12.e032569.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.08.012"},{"key":"2025121400422537000_9.12.e032569.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.10541"},{"key":"2025121400422537000_9.12.e032569.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.30466"},{"key":"2025121400422537000_9.12.e032569.5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/acr.22921","article-title":"Use of rituximab in systemic lupus erythematosus: a single center experience over 14 years","volume":"69","author":"Aguiar","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025121400422537000_9.12.e032569.6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318190f170"},{"key":"2025121400422537000_9.12.e032569.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.10.009"},{"key":"2025121400422537000_9.12.e032569.8","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313503912"},{"key":"2025121400422537000_9.12.e032569.9","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/rheumatology\/kex395","article-title":"Short-Term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles lupus assessment group biologics register","volume":"57","author":"McCarthy","year":"2018","journal-title":"Rheumatology"},{"key":"2025121400422537000_9.12.e032569.10","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310395802"},{"key":"2025121400422537000_9.12.e032569.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233"},{"key":"2025121400422537000_9.12.e032569.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359"},{"key":"2025121400422537000_9.12.e032569.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"2025121400422537000_9.12.e032569.14","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The British Society for rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology"},{"key":"2025121400422537000_9.12.e032569.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker526"},{"key":"2025121400422537000_9.12.e032569.16","first-page":"449","article-title":"Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian multicentre registry","volume":"33","author":"Iaccarino","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2025121400422537000_9.12.e032569.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.079418"},{"key":"2025121400422537000_9.12.e032569.18","doi-asserted-by":"crossref","DOI":"10.1186\/ar2076","article-title":"Differential effects on BAFF and April levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"8","author":"Vallerskog","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2025121400422537000_9.12.e032569.19","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025121400422537000_9.12.e032569.20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: danger ahead?","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2025121400422537000_9.12.e032569.21","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S"},{"key":"2025121400422537000_9.12.e032569.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.11354"},{"key":"2025121400422537000_9.12.e032569.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.23678"},{"key":"2025121400422537000_9.12.e032569.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2025121400422537000_9.12.e032569.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"2025121400422537000_9.12.e032569.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem112"},{"key":"2025121400422537000_9.12.e032569.27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.autrev.2016.02.019","article-title":"Predictors of flares in systemic lupus erythematosus: preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review","volume":"15","author":"Floris","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2025121400422537000_9.12.e032569.28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh624"},{"key":"2025121400422537000_9.12.e032569.29","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2025121400422537000_9.12.e032569.30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025687","article-title":"Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol","volume":"9","author":"Teng","year":"2019","journal-title":"BMJ Open"},{"key":"2025121400422537000_9.12.e032569.31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep396"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-032569","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:42:33Z","timestamp":1765701753000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-032569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,16]]},"published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1136\/bmjopen-2019-032569"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-032569","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}